APPLICATION
Application Note
The peptide is used for blocking the antibody activity of anti-CD209 (cat. No GTX25715). It usually blocks the antibody activity completely in Western blot by incubating the peptide with an equal volume of antibody for 30 min at 37ºC.
PROPERTIES
Form
Liquid
Buffer
PBS, 0.1% BSA
Preservative
0.02% Sodium azide
Storage
Store the peptide at -20ºC, stable for one year.
Concentration
0.20 mg/ml (Please refer to the vial label for the specific concentration.)
Conjugation
Unconjugated
Note
For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.
TARGET
Synonyms
Cd209 Molecule , Cdsign , Clec4L , Dc-Sign , Dc-Sign1 , Cd209
Background
Dendritic cells (DCs) that control immune responses were recently found to capture and transport HIV from the mucosal area to remote lymph nodes, where DCs hand over HIV to CD4+ T lymphocytes. DCs also amplify the amount of virus and extend the duration of viral infectivity. Multiple strains of HIV-1, HIV-2 and SIV bind to DCs via DCSIGN (also termed CD209). ICAM-3 is the natural ligand for DC-SIGN. A DC-SIGN homologue (termed DC-SIGNR, L-SIGN, and DCSIGN2) was identified recently. DC-SIGN forms a novel gene family with DC-SIGNR and many alternatively spliced isoforms of DC-SIGN and DC-SIGNR. The expression of DC-SIGN was found in mucosal tissues including placenta, small intestine, and rectum.
Research Area
REFERENCE
There are currently no references for DC-SIGN peptide (GTX26091). Be the first to share your publications with this product.
REVIEW
There are currently no reviews for DC-SIGN peptide (GTX26091). Be the first to share your experience with this product.